Treatment of Hemodialysis-Associated Adynamic Bone Disease with Teriparatide (PTH1-34): A Pilot Study.

Cejka D, Kodras K, Bader T, Haas M

Kidney & blood pressure research24 Jun 2010Cited by 75 (Europe PMC)

PMID20588059DOI10.1159/000316708PepBankPUB-20588059

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, teriparatide treatment was linked to increased lumbar spine BMD from pretreatment.
In plain wordsIn dialysis patients with adynamic bone disease, teriparatide treatment was linked to increased spine bone density from pretreatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Lumbar spine BMD
0.885 g/cm(2)
pretreatment
Lumbar spine BMD
0.914 g/cm(2)
6 months
Source sentences
Summary
Teriparatide therapy led to a significant increase in lumbar spine (0.885 ± 0.08 vs. 0.914 ± 0.09 g/cm(2), p < 0.02), but not femoral neck (0.666 ± 0.170 vs. 0.710 ± 0.189 g/cm(2), p = 0.18) BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805901
02HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, femoral neck BMD did not change significantly during teriparatide treatment.
In plain wordsIn dialysis patients with adynamic bone disease, femoral neck bone density did not change significantly from pretreatment during teriparatide therapy.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeFemoral neck BMD
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Measurements
Femoral neck BMD
0.666 g/cm(2)
pretreatment
Femoral neck BMD
0.71 g/cm(2)
6 months
Source sentences
Summary
Teriparatide therapy led to a significant increase in lumbar spine (0.885 ± 0.08 vs. 0.914 ± 0.09 g/cm(2), p < 0.02), but not femoral neck (0.666 ± 0.170 vs. 0.710 ± 0.189 g/cm(2), p = 0.18) BMD.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805902
03HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, monthly lumbar spine BMD changes improved significantly during teriparatide treatment versus pretreatment.
In plain wordsIn dialysis patients, teriparatide treatment was linked to improved monthly spine bone density changes compared with pretreatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMonthly lumbar spine BMD change
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared to pretreatment values, calculated monthly changes in BMD improved significantly in both the lumbar spine and femoral neck (p < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805903
04HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, monthly femoral neck BMD changes improved significantly during teriparatide treatment versus pretreatment.
In plain wordsIn dialysis patients, teriparatide treatment was linked to improved monthly femoral neck bone density changes compared with pretreatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseMonthly femoral neck BMD change
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Compared to pretreatment values, calculated monthly changes in BMD improved significantly in both the lumbar spine and femoral neck (p < 0.02).
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805904
05HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, serologic bone turnover markers did not change significantly during teriparatide treatment.
In plain wordsIn dialysis patients, blood markers of bone turnover did not change significantly from pretreatment during teriparatide therapy.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeSerologic bone turnover markers
Study
n = 7
Comparator
Pretreatment
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in serologic markers of bone turnover and CAC scores were not statistically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805905
06HumanObservational studyEfficacy outcome
In hemodialysis patients with adynamic bone disease, coronary artery calcification scores did not change significantly during teriparatide treatment.
In plain wordsIn dialysis patients, coronary artery calcification scores did not change significantly from pretreatment during teriparatide therapy.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeCoronary artery calcification score
Study
n = 7
Comparator
Pretreatment
Outcome group
Tissue calcification · Cardiovascular
Studied dose
20 μg/day · subcutaneous · 6 monthsAs given in this study (human).
Source sentences
Summary
Changes in serologic markers of bone turnover and CAC scores were not statistically significant.
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hemodialysis patients with ABD and a median iPTH level of 22 pg/ml were evaluated in this open-label, prospective, 6-month observational pilot-study. All patients received 20 μg teriparatide/day subcutaneously. Serologic bone markers, BMD and coronary artery calcification (CAC) were measured a…
Report a problemFND-2058805906

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Journal Article

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.